Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon May 10, 2011 1:36pm
294 Views
Post# 18554788

RE: Raven's Q1

RE: Raven's Q1"DT_CORE have you heard about anything brewing?"

Can't say that I have anything "brewing" as of late, other than management is finally feeling the heat and the board getting a bit impatient with the current share price. With respect to Raven and HEM announcing on the same date I wouldn't read anything into it (just coincidence). Public companies can't have a deal in place and then time their announcement of a deal, rather they would need to issue a press release very quickly after a deal has been accepted (and sometimes they press release if a "real" deal was proposed and not accepted, e.g. Potash Corp).
Bullboard Posts